<qa>  What is the PK of FFUMECVI in Chinese healthy population?This is an open-label study to evaluate the PK of FFUMECVI in dose combinations of 10062.525 mcg after single and repeat dose administration from a DPI in healthy Chinese subjects. This study will evaluate the systemic pharmacokinetics PK, of FFUMECVI in Chinese healthy population when administered using dry powder inhaler DPIas a blended combination of UMECVI in one strip and FF in the second strip in dose combinations of 10062.525 mcg. The triple, fixed dose combination product Fluticasone furoateFF Vilanterol VI Umeclidinium bromide UMEC with new configuration enables the delivery of inhaled long-acting muscarinic antagonist LAMA, Long-acting beta2 agonist LABA and inhaled corticosteroid ICS from a single device. Approximately 16 subjects will be enrolled in the study. After taking into account the allowable time windows for screening, treatment and follow-up, a subject will be in the study for a maximum duration of 6-7 weeks. 